Random plasma concentrations of voriconazole decline over time

Journal of Infection

Volumn 55, Issue 5, 2007, Pages

  Mulanovich, Victor ^a   Lewis, Russell E ^a   Raad, Issam I ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Fungal infections; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; FEMALE; HEMATOLOGIC MALIGNANCY; HISPANIC; HUMAN; MALE; MEDICAL RECORD; MYCOSIS; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

ANTIFUNGAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLASMA; PYRIMIDINES; RETROSPECTIVE STUDIES; TIME FACTORS; TRIAZOLES;

EID: 35348976535     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.07.019     Document Type: Article

References (4)

1. Theuretzbacher U., Ihle F., and Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45 (2006) 649-663
2. Trifilio S., Ortiz R., Pennick G., Verma A., Pi J., Stoser V., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35 (2005) 509-513
3. Trifilio S., Pennick G., Pi J., Zook J., Golf M., Kaniecki K., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109 (2007) 1532-1535
4. Smith J., Safdar N., Knasinski V., Simmons W., Bhavnani S.M., Ambrose P.G., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50 (2006) 1570-1572